Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
December 2019
-
Featured NewsNovartis R&D Day
Novartis shares progress in advancing its industry-leading R&D pipeline. We are uniquely positioned to deliver transformational treatments through our scale, focus on innovative medicines, diverse range of therapeutic areas and exposure to cutting-edge platforms.
-
Media ReleaseNovartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters highlighted at R&D DayUniquely positioned with global scale, focus on innovative medicines, diversification across therapeutic areas and exposure to cutting-edge platforms60 projects in Phase 2 pipeline with 10+ advancing…
-
Key ReleaseNovartis tender offer for The Medicines Company commencesBasel, December 5, 2019 — Novartis AG (NYSE: NVS) (“Novartis”) today announced that its indirect wholly-owned subsidiary, Medusa Merger Corporation, a Delaware corporation (“Purchaser”), has…
-
Featured NewsAmazon Web Services (AWS) announces strategic collaboration with Novartis to accelerate digital transformation of its business operations
We’re collaborating with AWS to build an enterprise-wide data and analytics platform to transform the way medicines are manufactured and delivered.
-
Media ReleaseNovartis breadth of data at 2019 ASH demonstrates commitment to reimagining medicine in hematology through innovative therapeutic platformsWith more than 140 abstracts, Novartis continues its leadership in hematology innovation Data for MBG453, an innovative anti-TIM-3 immunotherapy, with decitabine on preliminary response rates in…
-
Featured NewsBehind the research driving our data at medical conferences
Novartis data at 2019 ASH and SABCS underscore our evolving R&D approach in innovative platforms to reimagine medicine and help improve patient outcomes.
November 2019
-
Featured NewsNovartis opens facility for innovative cell and gene therapies in Switzerland
New cell and gene manufacture in Stein offers hope for patients around the globe.
-
Key ReleaseNovartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of deathOver 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL…
-
Media ReleaseNovartis launches Innovation Prize for Assistive Tech to encourage new technologies that address unmet needs of the multiple sclerosis communityThe Novartis Innovation Prize: Assistive Tech for Multiple Sclerosis (MS) identifies and embraces technology that aims to improve mobility and daily life for people living with MS Applications are…
-
Media ReleaseNovartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEFEntresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF, compared to valsartan1 Entresto, compared to valsartan, demonstrated…
-
Key ReleaseNew Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell diseaseSickle cell pain crises are unpredictable, severe events associated with life-threatening complications1 Adakveo reduced the annual rate of sickle cell pain crises by 45% compared to placebo (1.…
-
Media ReleaseNovartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS)If approved, Mayzent® (siponimod) will be the first and only oral treatment specifically indicated for patients with active secondary progressive multiple sclerosis (SPMS) in Europe[1]) CHMP…
Pagination
- ‹ Previous page
- 1
- …
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- …
- 152
- › Next page